Alembic Pharmaceuticals Q1 FY27 Results

Consolidated Revenue from Operations: ₹2,149.77 crore
Consolidated Profit for the Period: ₹173.07 crore

Reader Takeaway: Revenue and profit growth driven by strong pharma performance; standalone profit surge is a key highlight.

What just happened

Alembic Pharmaceuticals Ltd. announced its financial results for the first quarter of fiscal year 2027 (ended June 30, 2026). The company reported consolidated revenue from operations of ₹2,149.77 crore, marking an increase from ₹1,710.72 crore in the same quarter last year. Consolidated profit for the period stood at ₹173.07 crore, up from ₹154.38 crore year-on-year.

On a standalone basis, revenue from operations was ₹1,868.06 crore, an increase from ₹1,494.17 crore in the prior year. Standalone profit for the quarter surged to ₹196.96 crore from ₹103.52 crore in the corresponding period of FY26.

Why this matters

The reported growth in both revenue and profit signifies a positive performance trend for Alembic Pharmaceuticals. The substantial increase in standalone profit highlights operational efficiency or specific business drivers. Investors will view these results as a sign of the company's expanding market presence and profitability within the pharmaceutical sector.

The backstory

Alembic Pharmaceuticals operates solely within the pharmaceuticals business segment. The Board of Directors approved these financial results on August 4, 2026. The company's financial reports have consistently been subject to auditor review.

What changes now

Investors have received updated financial metrics that reflect year-on-year growth. The clear performance indicators from both consolidated and standalone statements will aid in evaluating the company's current standing and future potential. The unqualified auditor's report provides confidence in the reported numbers.

Risks to watch

While the results show growth, investors should monitor the sustainability of these gains and any potential margin pressures in future reporting periods, especially given the operational focus on a single segment.

Peer comparison

(No specific peer comparison data is available in the provided filing.)

Context metrics (time-bound)

Consolidated Revenue from Operations for Q1 FY27: ₹2,149.77 crore (vs ₹1,710.72 crore in Q1 FY26)
Consolidated Profit for the Period for Q1 FY27: ₹173.07 crore (vs ₹154.38 crore in Q1 FY26)
Standalone Revenue from Operations for Q1 FY27: ₹1,868.06 crore (vs ₹1,494.17 crore in Q1 FY25)
Standalone Profit for the Period for Q1 FY27: ₹196.96 crore (vs ₹103.52 crore in Q1 FY25)

What to track next

Investors should track Alembic Pharmaceuticals' performance in subsequent quarters, focusing on continued revenue growth, profit margins, and any new product launches or market expansions within its core pharmaceutical business.